Helixomer

Helixomer is a private, preclinical biotech firm pioneering a novel drug design platform that combines RNA origami (RNAO) with aptamers to create more effective nanodrugs. Its core technology aims to overcome the historical limitations of aptamers—such as low efficacy and rapid clearance—by arranging multiple aptamers on a stable, non-immunogenic RNA scaffold. The company is applying this modular, 'plug-and-play' platform to build a pipeline in oncology, neurodegenerative disorders, and cardiovascular disease, positioning itself as a next-generation RNA medicine developer.

Patented RNA Origami (RNAO) platform that structurally arranges multiple aptamers on a stable, non-immunogenic RNA nanostructure to significantly enhance binding efficacy and therapeutic availability, produced using standard mRNA manufacturing processes.

Helixomer competes in the broader RNA therapeutics and targeted drug delivery space against large pharma, antibody developers, and other aptamer-focused biotechs. Its differentiation lies in its structural approach to aptamer enhancement, but it must demonstrate superior efficacy and safety to gain traction in a crowded field.